Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Tel Aviv
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Vaxil Bio Ltd

+ Add to Watchlist

VAXL:IT

57.00 ILs 0.70 1.24%

As of 10:24:08 ET on 05/06/2015.

Company Profile for Vaxil Bio Ltd (VAXL)

Vaxil Bio Limited is a clinical stage company developing a new class of synthetic T-cell therapeutic and preventive vaccines with promiscuous MHC class I and II binding, based on its proprietary VaxHit technology.

Contact Information

Vaxil Bio Ltd

Bl 13A, 13 Einstein st.
Weizmann Science Park
Nes Ziona, 74036
Israel
Phone: 972-8-939-6948
Fax: 972-8-939-6996

Key Executives for Vaxil Bio Ltd (VAXL)

Lior CarmonFounder/CEO/Head:ResearchJulian LevyPresident/CFO
Riva KovjazinDirector:ResearchOfira MoranClinical Trials Monitoring

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil